220 related articles for article (PubMed ID: 37754542)
1. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J; Vijayvergia N
Curr Oncol; 2023 Sep; 30(9):8653-8664. PubMed ID: 37754542
[TBL] [Abstract][Full Text] [Related]
2. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia.
Popa Ilie IR; Georgescu CE
Neuroendocrinology; 2023; 113(2):262-278. PubMed ID: 34348340
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G; Wang Y; Zhang H; She X; Yang J
Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
[TBL] [Abstract][Full Text] [Related]
7. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
Ye C; Yuan CH; Li G; Zheng L; Xiu DR
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
[TBL] [Abstract][Full Text] [Related]
8. The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms.
Zhang WH; Wang WQ; Gao HL; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188311. PubMed ID: 31442475
[TBL] [Abstract][Full Text] [Related]
9. "Present and future of immunotherapy in Neuroendocrine Tumors".
Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs): The Role of Checkpoint Inhibitors.
Arrivi G; Fazio N
Curr Cancer Drug Targets; 2022 Aug; 22(8):629-638. PubMed ID: 35034595
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
12. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions.
Fang L; Arvind D; Dowlati A; Mohamed A
J Neuroendocrinol; 2021 Mar; 33(3):e12943. PubMed ID: 33724586
[TBL] [Abstract][Full Text] [Related]
13. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system.
Pan WX; Zhang XM; Hao SL; Han W
World J Gastroenterol; 2023 Jul; 29(26):4174-4185. PubMed ID: 37475845
[TBL] [Abstract][Full Text] [Related]
14. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
17. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
[TBL] [Abstract][Full Text] [Related]
18. Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives.
Bai R; Li W; Cui J
Cancer Biol Med; 2022 Oct; 19(12):1649-61. PubMed ID: 36245210
[TBL] [Abstract][Full Text] [Related]
19. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
